The Inspire hypoglossal nerve stimulator dominates sleep apnea advertising. You have probably seen the commercials. A patient clicks a small remote before bed. The tongue stays forward. No mask. Problem solved. What the ads leave out is significant: the $30,000 to $65,000 price tag, the FDA Class 1 recall in 2024, the 42% reoperation rate found in adverse event data, and the strict eligibility criteria that disqualify most sleep apnea patients before they even walk into the surgeon's office.

On the other end of the spectrum sits the nasal stent — a soft silicone tube you insert in 10 seconds, costing under $50. It addresses a completely different patient population. Comparing these two treatments is not about declaring a winner. It is about understanding where you actually fall on the sleep apnea severity spectrum and which approach matches your diagnosis, your anatomy, and your budget.

This article breaks down what the STAR trial data actually shows, what patients report after living with the implant, who genuinely qualifies for Inspire, and why most people with sleep-disordered breathing need something far less invasive.

How the Inspire Implant Actually Works

The Inspire system is a hypoglossal nerve stimulator — a surgically implanted device that sends electrical pulses to the nerve controlling tongue movement. Three components get placed inside your body during a 2-3 hour outpatient surgery under general anesthesia:

The surgery requires two to three incisions: one below the jawline, one near the collarbone, and sometimes one along the ribcage. Most patients go home the same day. But — and this is critical — the device stays off for a full month after surgery. Your body needs to heal before any stimulation begins. Only after that waiting period does your sleep specialist activate the implant and begin calibrating the settings.

What the STAR Trial Data Actually Shows

The STAR trial (Stimulation Therapy for Apnea Reduction) is the landmark study behind Inspire's FDA approval. It enrolled 126 CPAP-intolerant patients across multiple centers. The results are genuinely impressive for the right patient — but they come with important context that marketing materials consistently omit.

At five years, 97 of the original 126 participants remained in the study. Sleepiness and quality-of-life scores continued improving, with normalization rates climbing from 33% to 78% for sleepiness and 15% to 67% for quality of life. These are meaningful, sustained improvements.

But here is what you rarely hear: 22% of participants never reached an AHI below 15. Roughly one in five patients went through surgery, spent $30,000 or more, recovered for a month, and did not achieve the target outcome. The trial also excluded anyone with BMI above 32 (later expanded to 40 for FDA approval), anyone with concentric palatal collapse, and anyone whose apnea was primarily central rather than obstructive. The real-world patient population is far more varied than this carefully selected trial group.

Who Actually Qualifies for Inspire (and Who Does Not)

Inspire's marketing reach far exceeds its actual patient pool. The eligibility criteria are strict, and for good reason — the device only works for a specific type of airway obstruction. Here is the full qualification checklist:

That DISE requirement alone eliminates a significant portion of candidates. Complete concentric collapse — where the soft palate closes like a drawstring — means the tongue-forward movement from Inspire cannot open the airway. Patients with this anatomy need a different surgical approach entirely.

Insurance adds another layer. While the FDA approved Inspire for BMI up to 40, most private insurers cap coverage at BMI 32 or 35. Medicare requires BMI below 35. Given that obesity is one of the primary risk factors for OSA, this rules out a large percentage of the people who need treatment most.

The True Cost of Inspire Over 10 Years

The sticker price of Inspire — the device plus surgery — runs between $30,000 and $65,000 depending on your hospital, surgeon, and geographic location. But that is not the full financial picture. Here are the costs that accumulate:

• Initial surgery: $30,000–$65,000 (device + procedure + anesthesia + facility fees)
• Insurance copay: $5,000–$15,000 out of pocket even with coverage. Medicare patients pay roughly $5,330 at outpatient surgical centers
• Battery replacement surgery: Required every 11 years. The Inspire V model may extend this, but it still means another outpatient procedure, another anesthesia session, and another recovery period
• Annual follow-ups: Sleep studies and device calibration appointments, typically $200–$500 per visit
• Potential revision surgery: If the lead migrates, the device malfunctions, or stimulation settings cannot achieve adequate results, additional surgery may be needed

For comparison, a Back2Sleep nasal stent yearly subscription costs €299 per year. Over 10 years, that totals roughly €2,990 — a fraction of the out-of-pocket cost of Inspire, even with insurance. Obviously, these devices serve different severity levels. But for the millions of people with snoring or mild-to-moderate OSA, the non-invasive option eliminates every surgical risk at a tiny fraction of the price.

Complications, Adverse Events, and the 2024 FDA Recall

Every surgical implant carries risk. What matters is knowing the real numbers, not just the marketing-friendly ones. Here is what post-market data reveals about Inspire complications:

Context matters here. The 42.3% reoperation figure comes from reported adverse events, not the total implant population. Most Inspire patients never file an adverse event report. The STAR trial's controlled environment showed less than 2% serious adverse events. Real-world outcomes fall somewhere between those two numbers. But the gap between "less than 2%" and "42% of reported problems needed more surgery" is wide enough that patients deserve to understand both figures before consenting.

What Patients Actually Report After Living With Inspire

Clinical trial data tells one story. Living with an implanted nerve stimulator tells another. Patient forums, FDA adverse event reports, and independent review platforms reveal a mixed but telling picture.

The split is real. 95.6% satisfaction on RealPatientRatings across 422 verified reviews. Yet the FDA's own database contains reports of painful shocks, nerve damage requiring revision, and patients who discontinued use entirely. One patient described the stimulation as "literally a torture" that made sleep impossible. Another reported a 4.5-inch throat incision that had not healed four months after surgery, accompanied by severe vertigo episodes.

The tongue sensation — a light pulsing or tingling — is the most common adjustment challenge. Most patients adapt within two to three weeks. But "most" is not "all." Some find the electrical sensation disruptive enough that they turn the device off, defeating its purpose.

Inspire vs Genio: Two Competing Nerve Stimulators

Inspire is not the only hypoglossal nerve stimulator on the market. Nyxoah's Genio system received FDA approval based on its DREAM trial data, and it takes a fundamentally different surgical approach. If you are considering nerve stimulation, understanding both options matters.

Genio's single-incision approach and external battery eliminate two of Inspire's biggest concerns: chest surgery complications and the eventual battery replacement procedure. However, Inspire's closed-loop breathing sensor provides more precise stimulation timing. Neither device has proven decisively superior in head-to-head trials yet — study populations have been too small for definitive comparison.

The Treatment Ladder: Where Each Option Fits

Sleep medicine specialists do not jump straight to surgery. The established clinical approach follows a severity-based treatment ladder — starting with the least invasive, least expensive options and escalating only when they prove insufficient. Here is where the Inspire implant and nasal stents actually sit in that hierarchy:

The critical point: most people with sleep-disordered breathing fall into Steps 1 or 2. Snoring without significant apnea, mild OSA with AHI under 15, and even moderate cases often respond well to non-invasive approaches. Surgery is the last resort, not the first choice — no matter how compelling the advertising.

Inspire vs Nasal Stent: Complete Head-to-Head Comparison

The Science Behind Internal Nasal Stents

A 2024 systematic review and meta-analysis pooling data from 17 studies and 496 participants examined nasal dilators for sleep-disordered breathing. The findings clarify an important distinction: simple external nasal strips (like Breathe Right) show no statistically significant AHI improvement. But internal nasal stents that extend to the soft palate — like Back2Sleep — work through a different mechanism entirely.

Back2Sleep does not just widen the nostril opening. The stent reaches from the nostril to the soft palate, physically preventing the tissue vibration and partial collapse that generates snoring and mild obstructive events. Clinical data shows:

• REI reduction: 22.4 ± 14.1 to 15.7 ± 10.4 (p<0.01) — a statistically significant drop in respiratory events
• SpO2 improvement: Lowest oxygen saturation rose from 81.9% to 86.6% (p<0.01) — meaning less dangerous oxygen dipping during sleep
• Immediate onset: Most users report reduced snoring from the very first night of use
• Four sizes available: The starter kit includes S, M, L, and XL to match individual nasal anatomy

The adaptation period mirrors getting used to contact lenses — 3 to 5 days of mild awareness, then the sensation fades. Unlike CPAP, there are no straps, no hoses, no electricity, and no noise. Unlike Inspire, there is no surgery, no anesthesia, and no implanted hardware.

Making the Right Decision for Your Situation

Real Experiences With Non-Invasive Treatment

Frequently Asked Questions